Beam Therapeutics
BEAM
Performance
About Beam Therapeutics
Beam Therapeutics is a biotechnology company focused on developing precision genetic medicines using base editing to treat genetic diseases. The company emphasizes clinically validated delivery technologies, including electroporation, nonviral and viral modalities, to advance its base editing programs. With operations in locations such as Cambridge, Massachusetts and Durham, North Carolina, Beam aims to expand the potential of gene-based editing and bring novel therapies to patients through pipelines and clinical trials.
Recent News
Keep an Eye on These 15 Biotech Companies in 2026
Chinese Trial Backs Base-Editing Drug for Thalassaemia
Labiotech’s 15 Biopharma Companies to Watch in 2026
JPM26: Korro Bio Looks To Save Itself Despite Unenviable Position
Beam Therapeutics (BEAM): Among the Stocks That Could 10x Over the Next 5 Years
Wave To Work Alone on RNA Editor as AATD Picture Becomes Clearer
100% Pharma Tariffs, Lilly's Oral GLP-1 Approval, and a $12B Week in Biotech M&A – This Week in Biotech #94
